Also known as: Accelerated phase chronic myologenic leukemia / Accelerated Phase Chronic Myeloid Leukemia / Accelerated phase chronic myologenic leukaemia / Myeloid leukemia, chronic / Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Chronic myeloid leukemia / CML / Chronic myelogenous leukaemia / Chronic myelocytic leukaemia / Leukemia myelocytic chronic / Chronic myelogenous leukemia / Leukaemia myelocytic chronic / Chronic granulocytic leukemia / Leukaemias chronic myeloid / Chronic myelocytic leukemia / Chronic granulocytic leukaemia / Chronic myeloid leukaemia / Myeloid leukaemia, chronic
DrugDrug NameDrug Description
DB08901PonatinibPonatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.
DrugDrug NamePhaseStatusCount
DB04868Nilotinib1 / 2Recruiting1
DB08877Ruxolitinib1 / 2Recruiting1